An observational study in Retinitis Pigmentosa and Choroideremia, sponsored by Center for Eye Research Australia. Enrolling by invitation at 1 site in Australia. Per ClinicalTrials.gov, last updated 2024-08-23.
Sponsored by Center for Eye Research Australia · Observational
This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.
To observe and assess visual, orientation and mobility behavior with primary and adjunct vision processing (AVP) methods that may enhance the performance with the suprachoroidal retinal prosthesis (ScRP). To investigate the effectiveness of primary and AVP methods in the laboratory and real-world environments with the ScRP. Assess structural and functional ScRP stability with objective and subjective assessments. Record participant experiences and feedback with the ScRP.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
This study's planned enrollment of 7 is below the median of 52 across 87 observational studies indexed under Retinitis Pigmentosa.
Browse Retinitis Pigmentosa studies →Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who were implanted with a suprachoroidal retinal prosthesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Effectiveness of vision processing method in the laboratory.
Measure effectiveness of of the vision processing method via observational and quantitative data.
Time frame: 5 years.
Effectiveness of vision processing method in the 'real world' featured environment.
Measure the effectiveness of the vision processing method via observational qualitative and quantitative data in participant 'real world' featured environment.
Time frame: 5 years.
Device stability and functionality.
Monitor device stability with routine ophthalmic imaging, impedance and threshold testing.
Time frame: 5 years.
Participant experience.
Document participant anecdotal experience with the VP method in 'real world' environments.
Time frame: 5 years
Participant interview.
Interview participants to capture participant experience with the ScRP, determine differences in functional outcomes and utilise this information to improve assessment of functional outcomes.
Time frame: 5 years
Plan to share: No — There is not a plan to make IPD available.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 48 observational studies under Retinitis Pigmentosa, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 28. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for Eye Research Australia